Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 943,030
  • Shares Outstanding, K 147,579
  • Annual Sales, $ 170,280 K
  • Annual Income, $ -225,250 K
  • EBIT $ -165 M
  • EBITDA $ -152 M
  • 60-Month Beta 1.49
  • Price/Sales 5.20
  • Price/Cash Flow N/A
  • Price/Book 3.96

Options Overview Details

View History
  • Implied Volatility 145.91% ( +35.85%)
  • Historical Volatility 98.31%
  • IV Percentile 80%
  • IV Rank 22.62%
  • IV High 573.92% on 04/19/24
  • IV Low 20.76% on 10/03/24
  • Put/Call Vol Ratio 0.95
  • Today's Volume 123
  • Volume Avg (30-Day) 77
  • Put/Call OI Ratio 0.28
  • Today's Open Interest 1,619
  • Open Int (30-Day) 1,215

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.26
  • Number of Estimates 4
  • High Estimate -0.23
  • Low Estimate -0.27
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.27 +49.65%
on 11/21/24
7.07 -9.57%
on 12/10/24
+1.97 (+44.57%)
since 11/20/24
3-Month
3.98 +60.51%
on 09/25/24
7.07 -9.57%
on 12/10/24
+1.74 (+37.42%)
since 09/20/24
52-Week
2.28 +180.26%
on 04/19/24
7.07 -9.57%
on 12/10/24
+1.65 (+34.81%)
since 12/20/23

Most Recent Stories

More News
Adaptive Biotechnologies Announces New Data Highlighting the Actionability of clonoSEQ in Blood Cancer Treatment Decisions at ASH Annual Meeting

New data highlights clonoSEQ's effectiveness in guiding treatment decisions for patients with various blood cancers.Quiver AI SummaryAdaptive Biotechnologies Corporation has announced new data highlighting...

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies' clonoSEQ Test Featured in Record Number of Abstracts at 66th Annual ASH Meeting

Adaptive Biotechnologies' clonoSEQ test for MRD assessment will feature prominently at the ASH Annual Meeting 2024.Quiver AI SummaryAdaptive Biotechnologies Corporation announced that its clonoSEQ® test...

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies: Q3 Earnings Snapshot

Adaptive Biotechnologies: Q3 Earnings Snapshot

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies Reports Third Quarter 2024 Financial Results

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies to Report Third Quarter 2024 Financial Results on November 7, 2024

ADPT : 6.39 (+6.50%)
Adaptive Biotechnologies: Q2 Earnings Snapshot

Adaptive Biotechnologies: Q2 Earnings Snapshot

ADPT : 6.39 (+6.50%)
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The popular growth investor keeps adding to some of her favorite falling stocks.

SHOP : 108.95 (+1.76%)
NTLA : 12.18 (+0.83%)
ADPT : 6.39 (+6.50%)

Business Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 7.32
2nd Resistance Point 6.91
1st Resistance Point 6.65
Last Price 6.39
1st Support Level 5.99
2nd Support Level 5.58
3rd Support Level 5.32

See More

52-Week High 7.07
Last Price 6.39
Fibonacci 61.8% 5.24
Fibonacci 50% 4.67
Fibonacci 38.2% 4.11
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar